

Claims

1. Antibodies against T cells as a therapeutic for a prolonged immunosuppression and tumor cell elimination, wherein
 - a) the antibodies consist of at least two different groups A, B, which are administered at different times and in which at least one antibody type of group B differs from at least one antibody type of group A in the constant regions of their heavy chains, and
 - b) wherein group A, which is first applied once or several times, has a T-cell eliminating effect, whereas the other group B (which is applied at a different time) has a T-cell eliminating and/or T-cell antigen modulating effect.
2. The antibodies according to Claim 1, characterized in that one antibody type of group B is bispecific.
3. The antibodies according to Claim 1 or 2, characterized in that said one antibody type of group B is species-different vis-à-vis the antibody type of group A in its constant heavy chains.
4. The antibodies according to any one of Claims 1 to 3, characterized in that one antibody type of one of groups A, B is modified in its constant heavy chains by means of genetic engineering vis-à-vis an antibody type of the other group.
5. The antibodies according to any one of Claims 1 to 4, characterized in that one antibody type of one of groups A, B is modified in its constant heavy chains by introduction of chemical compounds vis-à-vis one antibody type of the other group (e.g. DNP-haptenized).